ABclonal is based in Woburn. It has raised $282M in total funding. Latest round: Series D.
ABclonal funding overview
ABclonal is based in Woburn. ABclonal has raised $282M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in December 2021. The round record for ABclonal runs through 2021; nothing later has been disclosed. Investors on record include CMB International Capital, HongShan, Lucion Venture Capital Group, Loyal Valley Capital, Taikang Asset Management. 5 distinct backers are named across the disclosed rounds.
ABclonal at a glance
Total raised
$282M
Latest round
Series D
Latest round date
December 2021
Headquarters
Woburn
Notable investors
CMB International Capital, HongShan, Lucion Venture Capital Group, Loyal Valley Capital, Taikang Asset Management
Frequently asked about ABclonal funding
How much has ABclonal raised?
ABclonal has raised $282M in total disclosed funding across the rounds on record.
Who has invested in ABclonal?
CMB International Capital, HongShan, Lucion Venture Capital Group, Loyal Valley Capital, Taikang Asset Management are named among the investors backing ABclonal.
What was the latest ABclonal funding round?
The most recent disclosed round is a Series D, announced in December 2021.
Where is ABclonal based?
ABclonal is based in Woburn.
When did ABclonal last raise?
The last disclosed ABclonal round closed in December 2021 at Series D.
ABclonal totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Woburn below to benchmark round size and investor mix.
